Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 2, 2001, Pages 132-141

  Kerbusch, Thomas ^a,b   Jansen, Rob L H ^a,b   Mathôt, Ron A A ^a,b   Huitema, Alwin D R ^a,b   Jansen, Myra ^a,b   Van Rijswijk, Ruud E N ^a,b   Beijnen, Jos H ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 DECHLOROETHYLIFOSFAMIDE; 3 DECHLOROETHYLIFOSFAMIDE; 4 HYDROXYIFOSFAMIDE; CHLOROACETALDEHYDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DRUG METABOLITE; IFOSFAMIDE; KETOCONAZOLE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME REGULATION; FEMALE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BAYES THEOREM; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HUMANS; IFOSFAMIDE; KETOCONAZOLE; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; RIFAMPIN; TIME FACTORS;

EID: 0034887811     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.117283     Document Type: Article

References (20)

1. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites
2. The enigma of ifosfamide encephalopathy
3. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide
4. Effects of the antifungal agents on the oxidative drug metabolism
5. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes
6. Inhibition and induction of cytochrome P450 and the clinical implications
7. Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism
8. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines
9. Determination of ifosfamide, 2- and 3-dechloroethylifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection
10. High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes
11. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
12. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients
13. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
14. Co-administration of cyclosporin enables oral therapy with paclitaxel
15. Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo
16. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans
17. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
18. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide